Detalles de la búsqueda
1.
Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update.
Blood
; 143(17): 1713-1725, 2024 Apr 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-38194692
2.
A phase II trial of netupitant/palonosetron for prevention of chemotherapy-induced nausea/vomiting in patients receiving BEAM prior to hematopoietic cell transplantation.
J Oncol Pharm Pract
; 30(2): 304-312, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-37151021
3.
Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse.
Blood
; 132(25): 2639-2642, 2018 12 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-30266774
4.
Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study.
Lancet Oncol
; 20(7): 998-1010, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31101489
5.
Outcomes of patients with secondary central nervous system lymphoma treated with chimeric antigen receptor T-cell therapy: A CIBMTR analysis.
Br J Haematol
; 2024 May 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-38797526
6.
Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis.
Biol Blood Marrow Transplant
; 24(6): 1163-1171, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29242111
7.
Safety and efficacy of polatuzumab vedotin + obinutuzumab for relapsed/refractory non-Hodgkin lymphomas: A phase IB/II study.
Am J Hematol
; 97(1): E24-E27, 2022 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34731510
8.
Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes.
Biol Blood Marrow Transplant
; 22(7): 1197-1205, 2016 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-27040394
9.
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet
; 385(9980): 1853-62, 2015 May 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-25796459
10.
Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation.
Biol Blood Marrow Transplant
; 20(11): 1729-36, 2014 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-25008330
11.
CAR T-Cell Immunotherapy in Minority Patients with Lymphoma.
NEJM Evid
; 3(4): EVIDoa2300213, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38776868
12.
Autologous haematopoietic cell transplantation for non-Hodgkin lymphoma with secondary CNS involvement.
Br J Haematol
; 162(5): 648-56, 2013 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-23829536
13.
Long-term Outcomes After Hematopoietic Cell Transplant in Peripheral T-Cell Lymphoma - The Oregon Health and Science University Experience.
Clin Lymphoma Myeloma Leuk
; 23(12): 874-881, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37741763
14.
Assessment of Healthcare Resource Utilization and Hospitalization Costs in Patients With Relapsed or Refractory Follicular Lymphoma Undergoing CAR-T Cell Therapy With Tisagenlecleucel: Results From the ELARA Study.
Transplant Cell Ther
; 29(1): 60.e1-60.e4, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36182104
15.
Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome.
Blood Adv
; 7(17): 4765-4772, 2023 09 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36508286
16.
Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma.
Blood Adv
; 7(18): 5579-5585, 2023 09 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-37522731
17.
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial.
Nat Med
; 28(2): 325-332, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34921238
18.
Can we truly define 'Fitness' for CAR-T therapy in large B cell lymphoma patients?
Chin Clin Oncol
; 13(1): 15, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-37953244
19.
Correction: First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL.
Oncotarget
; 10(38): 3827-3830, 2019 06 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-31217910
20.
Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS).
Lancet Haematol
; 6(5): e254-e265, 2019 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-30935953